You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Expansion of Immuno-CometChip Platform

    SBC: Amelia Technologies LLC            Topic: NIEHS

    Project SummaryThe objective of this supplementation request is to further our recent advances in the development of thewell Immuno CometChip assay results and build a prototypewell preformer giving the assay more utility and increasing commercial viability

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD, LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Clinical Screening Platform for Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIDDK

    AbstractA major shortfall in clinical care for diabetes is a rapid and accurate screen for progression to diseaseCurrent criteria involve HLA haplotypeand the presence of auto antibodiesAAGenome wide associated studiesGWASrevealed only immune associated genes including HLA as T D predictorsThe ability to differentiate from other diseases was very limitedPre typediabetesp T Dis now being identified ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Fibrin-Specific Nuclear Probe to Reduce LVAD Adverse Events

    SBC: CAPELLA IMAGING, LLC            Topic: NHLBI

    Despite the myriad major advances in cardiologythe prognosis for patients with severemedically refractive heart failureHFis exceedingly poorApproximatelydeaths occur annually in patients with HF who have endured an impaired quality of life often accompanied by significant economic and personal losses due to recurrent hospitalizationsAt leastof these deaths were directly related to severe heart fai ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. OC-Go: Facilitating fidelity and dissemination of evidence based treatment for childhood OCD via an interactive crowd-sourced patient-provider tool

    SBC: VIRTUALLY BETTER INC            Topic: 104

    The long term objective of this project is to leverage mobile technologies and crowdsourcing to create a new paradigm of evidence based treatment delivery and disseminationas current methods are often insufficientThe project seeks to refine and assess OC Goa HIPAA compliant web based clinician portal and patient side mobile application designed to increase patient adherence to evidence based treat ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. ErythroMer: Nanoscale Bio-Synthetic Red Cell Substitute

    SBC: KaloCyte Inc            Topic: NHLBI

    PROJECT SUMMARY There is need for an artificial oxygenOcarrier to substitute for banked blood in settings wherestored blood is unavailablepre hospital care transportaustere environmentsundeveloped countriesorundesirabletransfusion risk exceeds benefitTo address this needwe developedErythroMerEMa first inclass nano cyte blood substituteEM is a deformablecross linked polymeric nanoparticle that inco ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Translating Software Development from Concept to the Marketplace through the Innovation Corps

    SBC: Bayesic Technologies, LLC            Topic: 400

    PROJECT SUMMARYBayesic TechnologiesLLCproposes to participate in the I Corps program predicated on our STTR Phase I awardRGMADevelopment of a User friendly Bayesian Software PackageProof of ConceptThis project aims to meet researchersincreased demand to iuse Bayesian statistical methods to analyze data and iido so using easy to use software that is intuitiveinteractivetime efficientand incorporate ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. An unique patient population for clinical trials against noise-induced hearing loss

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIDCD

    AbstractNoise is the number one occupational and environmental hazardand noiseinduced hearing lossNIHLis one common form of sensorineural hearing deficitonly second to age related hearing lossCurrently no drug preventing NIHL is approved by the United States Food and Drug AdministrationFDAOne major challenge for the introduction of such interventions is the need to identify appropriate human popul ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Detection and Staging of Liver Fibrosis by Precise MRI (pMRI)

    SBC: INLIGHTA BIOSCIENCES L.L.C.            Topic: NIAAA

    Abstract Chronic liver injury due to alcoholmetabolic dysfunctionviral hepatitisor autoimmune disease results in liver inflammation and fibrosisLiver fibrosis will progress to cirrhosis which is estimated to affectof the world s populationThe major clinical consequences of cirrhosis are liver failure and hepatocellular carcinomaHCCboth of which increase the risk of deathAlcoholic liver diseaseALDi ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government